Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor

Assay and Drug Development Technologies

Volumn 9, Issue 4, 2011, Pages 394-402

  Harikumar, Kaleeckal G ^a   Cawston, Erin E ^a   Miller, Laurence J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ A RECEPTOR; GI 224329; LIGAND; REAGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG SCREENING; FLUORESCENCE POLARIZATION; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR LIBRARY; NONHUMAN; RECEPTOR BINDING;

ALLOSTERIC SITE; ANIMALS; BENZODIAZEPINES; CHO CELLS; CRICETINAE; DEVAZEPIDE; DRUG DISCOVERY; FLUORESCENCE; FLUORESCENCE POLARIZATION; HUMANS; INTRACELLULAR CALCIUM-SENSING PROTEINS; LIGANDS; PEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860389960     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0310     Document Type: Article

References (30)

1. Kenakin T, Miller L J: Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010;62:265-304.
2. Miller L J, Dong M, Harikumar KG, Lisenbee CS: Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem 2007;7:1166-1172.
3. Dufresne M, Seva C, Fourmy D: Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805-847.
4. Liddle RA: Cholecystokinin cells. Annu Rev Physiol 1997;59:221-242.
5. Rehfeld JF: Cholecystokinin. Clin Gastroenterol 1980;9:593-607.
6. Gaisano HY, Klueppelberg UG, Pinon DI, Pfenning MA, Powers SP, Miller L J: Novel tool for the study of cholecystokinin-stimulated pancreatic enzyme secretion. J Clin Invest 1989;83:321-325.
7. Fulcrand P, Rodriguez M, Galas MC, Lignon MF, Laur J, Aumelas A, Martinez J: 2-Phenylethyl ester and 2-phenylethyl amide derivative analogues of the Cterminal hepta- and octapeptide of cholecystokinin. Int J Pept Protein Res 1988;32:384-395.
8. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller L J: Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol 2002;61:1041-1052.
9. Dong M, Lam PC, Pinon DI, Abagyan R, Miller L J: Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry 2009;48:5303-5312.
10. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller L J: Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem 1998;273:12988-12993.
11. Harikumar KG, Miller L J: Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem 2005;280:18631-18635.
12. Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller L J: Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol 2004;65:28-35.
13. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller L J: Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 1997;272:24393-24401.
14. Cawston EE, Miller L J: Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol 2010;159:1009-1021.
15. Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller L J: Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem 2006;49:850-863.
16. Smeets RL, Ap IJ, Hermsen HP, Ophorst OJ, Van Emst-De Vries SE, De Pont JJ, Willems PH: Mutational analysis of the putative devazepide binding site of the CCK(A) receptor. Eur J Pharmacol 1997;325:93-99.
17. Gao F, Sexton PM, Christopoulos A, Miller L J: Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett 2008;18:4401-4404.
18. Kenakin TP: '7TM receptor allostery: Putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009;30:460-469.
19. May LT, Leach K, Sexton PM, Christopoulos A: Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2007;47:1-51.
20. Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller L J: Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem 2002;277:18552-18560.
21. Akgun E, Korner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller L J: Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem 2009;52:2138-2147.
22. Powers SP, Pinon DI, Miller L J: Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res 1988;31:429-434.
23. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller L J: Relationship between native and recombinant cholecystokinin receptors: Role of differential glycosylation. Pancreas 1996;13:130-139.
24. Harikumar KG, Hosohata K, Pinon DI, Miller L J: Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor. J Biol Chem 2006;281:2543-2550.
25. Harikumar KG, Miller L J: Use of fluorescence indicators in receptor ligands. Methods Mol Biol 2009;552:279-291.
26. Harikumar KG, Pinon DI, Miller L J: Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor. Biosci Rep 2006;26: 89-100.
27. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr., Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller L J, Queen KL, Rimele TJ, Smith DN, Sugg EE: Discovery of 1,5- benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem 1996;39:562-569.
28. Christopoulos A, Mitchelson F: Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J Pharm Pharmacol 1997;49:781-786.
29. Turcatti G, Zoffmann S, Lowe, JA 3rd, Drozda SE, Chassaing G, Schwartz TW, Chollet A: Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands. J Biol Chem 1997;272:21167-21175.
30. Tota MR, Strader CD: Characterization of the binding domain of the betaadrenergic receptor with the fluorescent antagonist carazolol. Evidence for a buried ligand binding site. J Biol Chem 1990;265:16891-16897.